• Defining the genetic cause of inherited ocular disorders.
• Investigating the molecular, cellular and pathophysiological basis of inherited ocular disorders (i.e. inherited retinal dystrophies and optic neuropathies).
• Bringing cure to patients with inherited retinal or optic nerve disease using antisense-oligonucleotide treatment, CRISPR/Cas mediated genome editing and gene augmentation therapy.

limits2vision is driven by a unique team of experts in retinal neurobiology, physiology, pathology, metabolism, and genetics, as well as specialists for computational neuroscience and machine learning. This interdisciplinary approach ensures a comprehensive education for PhD students.

We are proposing the following project to a PhD Student:
DE-1 – Krebs cycle aconitase deficiency in inherited retinal ganglion cell dysfunction: Functional validation of ACO2 variants in patients with optic atrophy and their metabolic impact

Further Details to this project and the international Research Training Program clicking this link limits2vision.net/projects/

The central goal of the RD TREAT Plan is to provide clinical proof of concept for effective gene- therapeutic, as well as the pharmacological treatment options in the treatment of PDE6A-linked retinopathies and related disorders, within 5 years after the start of this project. 
Link: www.eye-tuebingen.de/rd-treat

European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases
Link: https://www.progret.eu/